Anteris Technologies Reports Q1 2026 Financial Results with $494.6M in Net Sales and $22.9M Net Loss

Anteris Technologies Global Corp. reported its financial results for the first quarter of 2026, revealing a net sales figure of $494.6 million, a decrease of 11% compared to $556.0 million in the same period of 2025. The decline in revenue was primarily attributed to the expiration of a Transition Services Agreement with LeMaitre Vascular, which previously contributed $300,000 in sales during the first quarter of 2025. However, sales of tissue products to 4C Medical Technologies increased by $200,000 in the same timeframe. The company incurred a net loss of $22.9 million for the quarter, slightly higher than the $21.9 million loss reported in the prior year.

In terms of operational expenses, Anteris experienced a 6% increase in research and development (R&D) expenses, totaling $17.5 million, driven by costs associated with scaling manufacturing capabilities and activities related to the ongoing PARADIGM Trial. Selling, general, and administrative expenses rose by 22% to $6.9 million, reflecting higher employee-related costs and increased consulting expenses. The company also reported a significant increase in other non-operating income, which rose to $1.7 million from $0.1 million, largely due to interest earned on cash deposits following recent capital raises.

Anteris has made strategic advancements, including the completion of a public offering in January 2026, which raised approximately $230 million, and a private placement with Medtronic that generated an additional $90 million. These capital raises have bolstered the company's cash position, with cash and cash equivalents increasing to $283.2 million as of March 31, 2026, compared to $12.6 million at the end of 2025. The company has also expanded its employee headcount to support its R&D and operational needs, although specific figures were not disclosed.

The company is focused on advancing its DurAVR® Transcatheter Heart Valve (THV) System, with ongoing recruitment for the PARADIGM Trial, which aims to establish the safety and effectiveness of the device in treating severe aortic stenosis. Anteris has received U.S. Medicare reimbursement eligibility for the trial, which is expected to facilitate patient enrollment at U.S. study sites. The company anticipates that the trial will provide critical clinical evidence for obtaining Premarket Approval (PMA) from the FDA, a key milestone for commercialization.

Looking ahead, Anteris expects to continue incurring losses as it invests in R&D and operational capabilities. The company acknowledges the need for additional capital to fund its ongoing operations and clinical trials, and it may pursue various funding avenues, including equity offerings and strategic partnerships. Despite the challenges, Anteris remains committed to its long-term goals of bringing innovative cardiac solutions to market.